Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022
• Global Migraine Pipeline Drugs Assessment – Review, Potential, Clinical Trials • Global Migraine Drugs Share By Type – Acute and Prophylaxis • Company Analysis
(c) AZOTH Analytics
January 2018
Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential – Forecast to 2022 Global Coverage
Migraine Pipeline Drugs Assessment
Scope of the Study Country Coverage
Global Migraine Drugs Market – By Type (Acute and Prophylaxis)
Global Coverage
Global Migraine Pipeline Drugs Assessment Global Migraine Drugs Market
Country Coverage
Pipeline Drugs Coverage
United States
Drug X-1
United Kingdom
Drug X-2
Japan
Drug X-3
France
Drug X-4
Italy
Drug X-5
Germany
Drug X-6 Drug X-7
(2012-2016), By Value
Company Coverage
Amgen Allergan Eli Lilly Alder Pharmaceuticals Teva Pharmaceuticals Vernalis Pfizer Impax Laboratories Glaxo Smithkline
Global Migraine Drugs Market (2017-2022), By Value Breakdown-By Type - Acute and Prophylaxis) Global Migraine Drugs Market (2012-16), By Value Global Migraine Drugs Market
Migraine Drugs Market, By Value (2012-2016) Migraine Drugs Market, By Value (2017-2022)
Migraine Drugs Market Forecast By Value (2018-2022)
Product Benchmarking Policy and Regulatory Landscape Financial Analysis Sales EBITDA Business Strategy
(2017-22), By Value
(c) AZOTH Analytics
2
Table of Content S.No
Particulars
Page No.
1.
Research Methodology
16
2.
Executive Summary
17
3.
Migraine - An Overview
18
4.
3.1
Symptoms of migraine
18
3.2
Stages of Migraine
19
3.3
Types of Migraine
20
3.4
Types of migraine on the basis of frequency of occurrence
24
Treatment of Migraine
25
4.1
Goal of Migraine Treatment
26
4.2
Treatment of Migraine – Pharmacological and Non-Pharmacological
26
4.2.1
Pharmacological treatment of migraine
27
4.2.2
Pharmacological - Abortive
28
4.2.3
Pharmacological - Preventive
30
(c) AZOTH Analytics
3
Table of Content S.No
5.
Particulars
Page No.
4.2.4
Non-Pharmacological Treatment of Migraine
33
4.2.5
Non- Pharmacological - Surgical
34
4.2.6
Non- Pharmacological – Non-Surgical
35
Anti Migraine Pipeline Drugs
38
5.1
Anti-Migraine Pipeline Drugs (According to Mechanism of Working)
39
5.2
Anti Migraine Pipeline Drugs (Ergotamine) – Drug X-1
40
5.2.1
Description
41
5.2.2
Regulatory Milestones
42
5.2.3
Advantages & Disadvantages
43
5.2.4
Product Profile & Expected Launch
44
5.2.5
Clinical Trials and Status
45
5.2.6
Pivotal Clinical Trials and Results
46
5.2.7
Drug X-1 – Global Market Potential
48
5.2.8
Drug X-1 - 7Ps Analysis
50
(c) AZOTH Analytics
4
Table of Content S.No
Particulars 5.3
Anti Migraine Pipeline Drugs (Anti-5HT Receptor Agonist) – Drug X-2
Page No. 51
5.3.1
Description
52
5.3.2
Regulatory Milestones
53
5.3.3
Advantages & Disadvantages
54
5.3.4
Product Profile & Expected Launch
55
5.3.5
Clinical Trials and Status
56
5.3.6
Pivotal Clinical Trials and Results
58
5.3.7
Drug X-2 – Global Market Potential
60
5.3.8
Drug X-2 – 7Ps Analysis
62
5.4
Anti Migraine Pipeline Drugs (Anti CGRPs)
63
5.5
Anti Migraine Pipeline Drugs (Anti CGRPs) – By Drug
66
5.6
Anti Migraine Pipeline Drugs (CGRP Antagonist) - Drug X-3
67
5.6.1
Description
68
5.6.2
Regulatory Milestones
69
5.6.3
Advantages & Disadvantages
70
(c) AZOTH Analytics
5
Table of Content S.No
Particulars
5.7
Page No.
5.6.4
Product Profile & Expected Launch
71
5.6.5
Clinical Trials and Status
72
5.6.6
Pivotal Clinical Trials and Results
73
5.6.7
Drug X-3 – Global Market Potential
75
5.6.8
Drug X-3 – 7Ps Analysis
77
Anti Migraine Pipeline Drugs (Anti-CGRP Mab) - Drug X-4
80
5.7.1
Description
81
5.7.2
Regulatory Milestones
82
5.7.3
Advantages & Disadvantages
83
5.7.4
Product Profile & Expected Launch
84
5.7.5
Clinical Trials and Status
85
5.7.6
Pivotal Clinical Trials and Results
86
5.7.7
Drug X-4 – Global Market Potential
90
5.7.8
Drug X-4 – 7Ps Analysis
92
(c) AZOTH Analytics
6
Table of Content S.No
Particulars 5.8
5.9
Anti Migraine Pipeline Drugs (Anti-CGRP Mab) - Drug X-5
Page No. 93
5.8.1
Description
94
5.8.2
Regulatory Milestones
95
5.8.3
Advantages & Disadvantages
96
5.8.4
Product Profile & Expected Launch
97
5.8.5
Clinical Trials and Status
98
5.8.6
Pivotal Clinical Trials and Results
100
5.8.7
Drug X-5 – Global Market Potential
103
5.8.8
Drug X-5 – 7Ps Analysis
105
Anti Migraine Pipeline Drugs (Anti-CGRP Mab) - Drug X-6
106
5.9.1
Description
107
5.9.2
Regulatory Milestones
108
5.9.3
Advantages & Disadvantages
109
5.9.4
Product Profile & Expected Launch
110
(c) AZOTH Analytics
7
Table of Content S.No
Particulars
5.10
Page No.
5.9.5
Clinical Trials and Status
111
5.9.6
Pivotal Clinical Trials and Results
113
5.9.7
Drug X-6 – Global Market Potential
115
5.9.8
Drug X-6 – 7Ps Analysis
117
Anti Migraine Pipeline Drugs (Anti-CGRP Mab) - Drug X-7
118
5.10.1
Description
119
5.10.2
Regulatory Milestones
120
5.10.3
Advantages & Disadvantages
121
5.10.4
Product Profile & Expected Launch
122
5.10.5
Clinical Trials and Status
123
5.10.6
Pivotal Clinical Trials and Results
125
5.10.7
Drug X-7 – Global Market Potential
127
5.10.8
Drug X-7 – 7Ps Analysis
129
(c) AZOTH Analytics
8
Table of Content S.No
6.
7.
Particulars
Global Migraine Drugs Market: Growth and Forecast
Page No.
130
6.1
By Value (2012-2016)
131
6.2
By Value (2017-2022)
132
Global Migraine Drugs Market-By Type 7.1
7.2
7.3
135
Global Migraine Drugs Market, By Type : Breakdown (%)
135
7.1.1
Global Migraine Drugs Market- By Type: 2016 (%)
136
7.1.2
Global Migraine Drugs Market – By Type: 2022 (%)
137
Global Migraine Drugs Market- By Acute
139
7.2.1
By Value (2012-2016)
139
7.2.2
By Value (2017-2022)
139
Global Migraine Drugs Market- By Prophylaxis
140
7.3.1
By Value (2012-2016)
140
7.3.2
By Value (2017-2022)
140
(c) AZOTH Analytics
9
Table of Content S.No
8.
9.
10.
Particulars
Global Migraine Drugs Market: Country Analysis (U.S, U.K, Japan, France, Italy, Germany, ROW)
Page No.
141
8.1
U.S. Migraine Drugs Market, By Value (2012-2022)
142
8.2
U.K. Migraine Drugs Market, By Value (2012-2022)
144
8.3
Japan Migraine Drugs Market, By Value (2012-2022)
146
8.4
France Migraine Drugs Market, By Value (2012-2022)
148
8.5
Italy Migraine Drugs Market, By Value (2012-2022)
150
8.6
Germany Migraine Drugs Market, By Value (2012-2022)
152
8.7
ROW Migraine Drugs Market, By Value (2012-2022)
154
Market Dynamics
155
9.1
Migraine Drug Market Drivers
156
9.2
Migraine Drug Market Challenges
160
Company Profile
162
10.1.
163
Amgen
(c) AZOTH Analytics
10
Table of Content S.No
11.
Particulars
Page No.
10.2.
Allergan
164
10.3.
Eli Lilly
165
10.4.
Alder Pharmaceuticals
167
10.5.
Teva Pharmaceuticals
168
10.6.
Vernalis
169
10.7.
Pfizer
170
10.8.
Impax Laboratories
171
10.9.
Glaxo Smithkline
172
About Us
173
(c) AZOTH Analytics
11
List of Figures Figure No.
Figure Title
Page No.
Figure 1:
2 hour pain relief & pain free rates in patients treated with LEVADEX (MAP0004) compared to placebo (1 st pivotal trial)
47
Figure 2:
Improvement at two hours in people who took LEVADEX compared to Placebo (2 nd pivotal trial)
47
Figure 3:
Global Drug X-1 Market Size, By Value, Forecast, 2019-2022 (USD Billion)
48
Figure 4:
Percentage of patients achieving primary end point
59
Figure 5:
Percentage of patients achieving secondary endpoint
59
Figure 6:
Global Drug X-2 Market Size, By Value, Forecast, 2019-2022 (USD Million)
60
Figure 7:
Efficacy in 2 hour pain freedom
74
Figure 8:
Global Drug X-3 Market Size, By Value, Forecast, 2019-2022 (USD Billion)
75
Figure 9:
Reduction in Monthly migraine days – weeks 1 through 12
87
Figure 10:
Percentage of patients with ≥75% reduction in number of migraine days – weeks 1 through 24
88
Figure 11:
Percentage of patients with 100% response rate (no migraine in any given month) – months 1 through 6
89
Figure 12:
Global Drug X-4 Market Size, By Value, Forecast, 2019-2022 (USD Million)
90
Figure 13:
Global Drug X-5 Market Size, By Value, Forecast, 2019-2022 (USD Million)
103
Figure 14:
Global Drug X-6 Market Size, By Value, Forecast, 2019-2022 (USD Million)
115
Figure 15:
Monthly migraine days reduction vs placebo in previous prophylactic drugs failure group
125
Figure 16:
Reduction in days using acute pain medications in recent drug overuse group
125
Figure 17:
Global Drug X-7 Market Size, By Value, Forecast, 2019-2022 (USD Million)
127
Figure 18:
Global Migraine Drugs Market Size, By value, 2012-2016 (USD Billion)
131
Figure 19:
Global Migraine Drugs Market Size, By Value, Forecast, 2017-2022 (USD Billion)
132
(c) AZOTH Analytics
12
List of Figures Figure No.
Figure Title
Page No.
Figure 20:
Global consumption of chocolate confectionary, By volume (in 1000 metric tones)
134
Figure 21:
Global Migraine Drugs Market Share, By Type, 2016 (%)
136
Figure 22:
Global Migraine Drugs Market Share, By Type, 2022 (%)
137
Figure 23:
Global Migraine Drugs Market, By Acute, By Value, 2012-2016 (USD Million)
139
Figure 24:
Global Migraine Drugs Market, By Acute, By Value, 2017-2022 (USD Million)
139
Figure 25:
Global Migraine Drugs Market, By Prophylaxis, By Value, 2012-2016 (USD Million)
140
Figure 26:
Global Migraine Drugs Market, By Prophylaxis, By Value, 2017-2022 (USD Million)
140
Figure 27:
U.S. Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
142
Figure 28:
U.S. Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
142
Figure 29:
U.S Adult Migraine Patients, In Percentage
143
Figure 30:
U.S Migraine Patients, By gender, In Percentage
143
Figure 31:
U.K Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
144
Figure 32:
U.K. Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
144
Figure 33:
U.K. Migraine Patient, In Percentage
145
Figure 34:
NHS Budget for mental illness, In Billion
145
Figure 35:
Japan Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
146
Figure 36:
Japan Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
146
Figure 37:
Japan Migraine Patient out of total population, In Percentages
147
Figure 38:
France Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
148
Figure 39:
France Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
148
(c) AZOTH Analytics
13
List of Figures Figure No.
Figure Title
Page No.
Figure 40:
France Migraine Patient, In Percentage
149
Figure 41:
Unemployment rate in France in percentage
149
Figure 42:
Italy Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
150
Figure 43:
Italy Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
150
Figure 44:
Italy Migraine Patient out of total population, In Percentages
151
Figure 45:
Italy Unemployment rate, In Percentages
151
Figure 46:
Germany Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
152
Figure 47:
Germany Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
152
Figure 48:
Germany Migraine Patient out of total population, In Percentages
153
Figure 49:
First Time asylum application, In Number
153
Figure 50:
ROW Migraine Drugs Market, By Value, 2012-2016 (USD Billion)
154
Figure 51:
ROW Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
154
Figure 52:
ROW Migraine Drugs Market, By Value, 2017-2022 (USD Billion)
165
(c) AZOTH Analytics
14
Research Methodology For our study of Migraine Drugs Market, we have conducted comprehensive secondary research followed by an extensive primary research. In the process of secondary research, we have scrutinized industry documents, accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva) and our internal knowledge base. In the process of primary research, we have interviewed various industry experts across the value chain of the Migraine Drug industry.
For evaluating the market size of pipeline drugs, both primary and secondary research has been conducted to validate the launch date, anticipated price and growth in the number of patients.
Market size of the actual period (2012-2016) has been evaluated on the basis of growth trends of the industry in the last five years, and confirming the findings through primary research. Annual reports of the companies are scanned to further validate the market size and to estimate the size of migraine drugs. All the relevant data points/ statistics in the forecast period are validated through relevant and reliable primary sources.
Report Focus: Global Migraine Drugs Market - Migraine Pipeline Drugs (Drug X-1, X-2, X-3, X-4, X-5, X-6, X-7) - By Type (Acute and Prophylaxis) - By Country (U.S., U.K, Japan, France, Italy, Germany) - Company Coverage (Amgen, Allergan, Eli Lilly, Alder Pharmaceuticals, Teva Pharmaceutical, Vernalis, Pfizer, Impax Laboratories, Glaxo Smithkline)
(c) AZOTH Analytics
16
Global Fremanezumab Market Figure 14: Global Drug X-1 Market Size, By Value, Forecast, 2019-2022 (USD Million)
CAGR 2019-2022 X%
2019
2020
2021
2022
Source: Azoth Analytics Estimates Xx Xx
Xx Xx Xx Xx Xx Xx
(c) AZOTH Analytics
115
Drug X-1 – 7Ps Analysis Patent
Phase
Pathway
Patient
Physician
Payer
Partner
(c) AZOTH Analytics
50
Global Migraine Drugs Market: Sizing and Growth (2012-2016) Increase in Global Stress levels coupled with growing awareness regarding migraine and availability of its drugs propelled growth in migraine drugs market. Figure 18: Global Migraine Drugs Market Size, By value, 2012-2016 (USD Billion) CAGR 2012-2016 X%
2012
2013
2014
2015
2016
Source: Azoth Analytics Estimates Xx Xx Xx Xx Xx Xx Xx Xx
(c) AZOTH Analytics
131
Global Heart Valve Devices Market, By Value U.S. Replacement Migraine Drugs Market Figure 27: U.S. Migraine Drugs Market, By Value,
Figure 28: U.S. Migraine Drugs Market, By Value,
2012-2016 (USD Billion)
2017-2022 (USD Billion) CAGR 2017-2022
CAGR 2012-2016
X%
X%
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Source: Azoth Analytics Estimates Xx Xx
Xx Xx Xx Xx Xx Xx
(c) AZOTH Analytics
142
About Azoth Analytics Pvt Ltd.
Azoth Analytics is a business research and analytics firm that creates in-depth research reports and provides customized research solutions and consultancy Application. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts).
Disclaimer: Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis
provided in the report are meant for customers’ internal use only and not for general publication or disclosure to third parties.
(c) AZOTH Analytics
22